Prescription to over-the-counter switching of drugs: Methodological issues and implications for non-sedating antihistamines

Disease Management and Health Outcomes

Volumn 13, Issue 2, 2005, Pages 83-92

  Rizzo, John A ^a   Ozminkowski, Ronald J ^b,c   Goetzel, Ron Z ^b,c,d  

^a STONY BROOK UNIVERSITY   (United States)

^b Cornell University ^*  (United States)

^c MEDSTAT GROUP   (United States)

^d Cornell Univ Inst for Plcy Res ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; CIMETIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FAMOTIDINE; HYDROCORTISONE; KETOCONAZOLE; LORATADINE; NICOTINE; NON PRESCRIPTION DRUG; PENICILLIN DERIVATIVE; RANITIDINE; TERBINAFINE; THIAZIDE DIURETIC AGENT; TIOCONAZOLE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; BLEEDING; CONSUMER; COST BENEFIT ANALYSIS; COST CONTROL; DEATH; DECISION MAKING; DEPRESSION; DIAGNOSTIC ERROR; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; MARKET; PATIENT EDUCATION; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SELF MEDICATION; SIDE EFFECT; STROKE; UNITED STATES;

EID: 17144412601     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200513020-00002     Document Type: Review

References (44)

1. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-336
2. Crystal-Peters J, Crown W, Goetzel R. The productivity costs of allergic rhinitis. Am J Manag Care 2000; 6 (3): 41-7
3. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 2 (Pt 1): 182-8
4. Tanner L, Reilly M, Meltzer E, et al. Effect of fexofenadine HCL on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 1999; 5: 235-7
5. Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83
6. Wilken J, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 372-80
7. Berger WE, Rosenwasser L, Atwater JS. Access to allergy care: implications for quality healthcare and public safety. Manag Care Q 2003 Spring; 11 (2): 8-11
8. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994; 73: 35-9
9. Malone D, Lawson K, Smith D, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1 Pt 1): 22-7
10. Goetzel R, Long S, Ozminkowski R, et al. Health, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med 2004; 46 (4): 1-15
11. Grubert N. The impact of Rx-to-OTC switching on the pharmaceutical market. Waltham (MA): Decision Resources Inc., 2001
12. Roper Starch Worldwide. Self care in the new millennium: American attitudes toward maintaining personal health and treatment [online]. Available from URL: http://www.chpa-info.org/web/press_room/statistics/pdfs/ chpa_final_report_revised_03_20.pdf [Accessed 2005 Feb 17]
13. Harrington P, Sheperd M. Analysis of the movement of prescription drugs to over-the-counter status. J Manag Care Pharm 2002; 8 (6): 499-508
14. Andersson F, Hatziandreu E. The costs and benefits of switching a drug from prescription-only to over-the-counter status. Pharmacoeconomics 1992; 2 (5): 388-96
15. Temin P. Costs and benefits of switching drugs from Rx to OTC. J Health Econ 1983; 2: 187-205
16. Dezil C. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): S2-6
17. Shih Y, Prasad M, Luce B. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis. Clin Ther 2002; 24 (4): 701-16
18. Sullivan P, Follin S, Nichol M. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care 2003; 41 (12): 1382-95
19. Ryan M, Yule B. The economics of switching drugs from prescription-only to over-the-counter availability [working paper]. Scotland: University of Aberdeen, 1988
20. Ryan M, Yule B. Switching drugs from prescription-only to over-the-counter availability: economic benefits in the United Kingdom. Health Policy 1990; 16: 233-9
21. Ryan M, Yule B. Benefits from switching drugs from prescription-only to over-the-counter availability: the UK experience. First Workshop on Strategies for the European Pharmaceutical Industry and Patient Interests; 1991 Jan 31-Feb 1; Brussels
22. Oster G, Huse D, Delea T, et al. The risks and benefits of an Rx-to-OTC switch. Med Care 1990; 28: 834-42
23. Gurwitz J, McLaughlin T, Fish L. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal agents. Health Serv Res 1995; 30 (5): 672-85
24. Tasch R, Goeree R, Henker CJ, et al. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation. Pharmacoeconomics 1996; 9 (1): 61-75
25. Rubin N, Foxman B. The cost-effectiveness of placing urinary tract infection treatment over the counter. J Clin Epidemiol 1996; 49 (11): 1315-21
26. Gianfrancesco F, Manning B, Wang R. Effects of prescription to OTC switches on out-of-pocket health care costs and utilization. Drug Benefit Trends 2002; 14 (3): 13-30
27. Shiffman S, Gitchell J, Pinney J, et al. Public health benefit of over-the-counter nicotine medications. Tob Control 1997; 6: 306-10
28. Kalish S, Bohn R, Avorn J. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use. Med Care 1997; 35 (1): 32-48
29. Andrade S, Gurwitz J, Fish L. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care 1999; 37 (4): 424-30
30. Lipsky M, Waters T, Sharp L. Impact of vaginal antifungal products on utilization of healthcare services: evidence from patient visits. J Am Board Fam Pract 1999; 13 (3): 178-82
31. Keeler T, Hu T, Keith A, et al. The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ 2002; 11: 389-402
32. Thorndike A, Rigotti N, Biener L. Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status. Am J Public Health 2002; 92 (3): 437-42
33. Hillman A, Eisenberg J, Pauly M, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362-5
34. Sacks H, Berrier J, Reitman D, et al. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 316: 450-5
35. Sampey C, Follin S. Second-generation antihistamines: the OTC debate. J Am Pharm Assoc 2001; 41 (3): 454-7
36. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998; 101: S352-6
37. National Transportation Safety Board. Testimony of NTSB Chairman Jim Hall regarding the Motor Carrier Safety Improvement Act of 1999 [online]. Available from URL: http://www.ntsb.gov/speeches/former/hall/jhc990929.htm [Accesssed 2005 Feb 17]
38. Gilmore T, Alexander B, Mueller B, et al. Occupational injury and medication use. Am J Intern Med 1996; 30: 234-9
39. American College of Allergy, Asthma, and Immunology (ACAAI). New national survey reveals Americans underestimate the consequences of allergies, 2002 [online]. Available from URL: http://www.biospace.com/ news_story.cfm?StoryID= 98152208&Full=1 [Accessed 2005 Feb 28]
40. Grossman J. One airway, one disease. Chest 1997; 111: 11S-6S
41. Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy 1989; 44: 116-22
42. Spector S. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997; 99: S773-80
43. Durham S. One airway: the link between allergic rhinitis and asthma. Adv Stud Med 2002; 2 (24): 861-6
44. Freudenheim M. Claritin's price falls, but drug costs more [online]. Available from URL: http://www.nytimes.com/top/news/health/topics/allergies/ index.html?offset=10 [Accessed 2005 Feb 28]